UY38999A - Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos - Google Patents
Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismosInfo
- Publication number
- UY38999A UY38999A UY0001038999A UY38999A UY38999A UY 38999 A UY38999 A UY 38999A UY 0001038999 A UY0001038999 A UY 0001038999A UY 38999 A UY38999 A UY 38999A UY 38999 A UY38999 A UY 38999A
- Authority
- UY
- Uruguay
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- methods
- degraders
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En el presente documento se proporcionan compuestos, composiciones y métodos útiles para degradar la proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora tipo 2 (PTPN2) y / o proteína tirosina fosfatasa no receptora tipo 1 (PTPN1), y para el tratamiento favorable de enfermedades relacionadas. sensibles al tratamiento con inhibidores de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962952097P | 2019-12-20 | 2019-12-20 | |
US201962952161P | 2019-12-20 | 2019-12-20 | |
US202063121721P | 2020-12-04 | 2020-12-04 | |
US202063125937P | 2020-12-15 | 2020-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38999A true UY38999A (es) | 2021-07-30 |
Family
ID=74206162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038999A UY38999A (es) | 2019-12-20 | 2020-12-21 | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4077319A1 (es) |
JP (1) | JP2023508914A (es) |
CN (1) | CN116194453A (es) |
AU (1) | AU2020407244A1 (es) |
CA (1) | CA3162364A1 (es) |
TW (1) | TW202136250A (es) |
UY (1) | UY38999A (es) |
WO (1) | WO2021127586A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202109024YA (en) | 2019-04-12 | 2021-09-29 | C4 Therapeutics Inc | Tricyclic degraders of ikaros and aiolos |
US20230167081A1 (en) * | 2020-04-30 | 2023-06-01 | President And Fellows Of Harvard College | 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders |
CN116648248A (zh) * | 2021-01-26 | 2023-08-25 | 成都茵创园医药科技有限公司 | 芳香化合物、含其的药物组合物及其应用 |
AU2022268977A1 (en) | 2021-05-05 | 2023-11-30 | Biogen Ma Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
WO2022271727A1 (en) * | 2021-06-21 | 2022-12-29 | Calico Life Sciences Llc | Degrader compounds and uses thereof |
UY39844A (es) | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
EP4384512A1 (en) * | 2021-08-10 | 2024-06-19 | Calico Life Sciences LLC | Protein tyrosine phosphatase targeting ligands |
CN118201923A (zh) * | 2021-10-15 | 2024-06-14 | 海南先声再明医药股份有限公司 | 三环类化合物 |
TW202333670A (zh) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 |
TW202415665A (zh) * | 2022-06-06 | 2024-04-16 | 美商樹線生物科學公司 | 三環喹啉酮bcl6雙功能降解劑 |
CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
EP3455218A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
IL273432B (en) * | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
-
2020
- 2020-12-18 WO PCT/US2020/066243 patent/WO2021127586A1/en unknown
- 2020-12-18 EP EP20845470.2A patent/EP4077319A1/en active Pending
- 2020-12-18 JP JP2022538068A patent/JP2023508914A/ja active Pending
- 2020-12-18 AU AU2020407244A patent/AU2020407244A1/en active Pending
- 2020-12-18 CA CA3162364A patent/CA3162364A1/en active Pending
- 2020-12-18 CN CN202080097241.6A patent/CN116194453A/zh active Pending
- 2020-12-21 TW TW109145346A patent/TW202136250A/zh unknown
- 2020-12-21 UY UY0001038999A patent/UY38999A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3162364A1 (en) | 2021-06-24 |
EP4077319A1 (en) | 2022-10-26 |
WO2021127586A1 (en) | 2021-06-24 |
JP2023508914A (ja) | 2023-03-06 |
TW202136250A (zh) | 2021-10-01 |
CN116194453A (zh) | 2023-05-30 |
AU2020407244A1 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38999A (es) | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos | |
UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
CO2021000447A2 (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
BR112019003866A2 (pt) | adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite) | |
BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
CL2019000732A1 (es) | Tratamiento avv de la enfermedad de huntington. | |
BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
DOP2023000145A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
NI202000085A (es) | Moduladores de la expresión de apol1 | |
EA202092487A1 (ru) | Ферменты кинурениназы человека и их применение | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
CO2022014499A2 (es) | Moduladores de nlrp3 | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. |